LOXL2 and glioma: In our study, LOXL2 can not only predict the prognosis of patients receiving TMZ treatment, but also regulates the Atg7-Erk1/2 signaling pathway to promote autophagy of glioma cells, and increases the tolerance of glioma cells to TMZ.